Summary

Overview
Global IgG4-Related disease market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.
IgG4-related disease (IgG4-RD) is an immune-mediated disorder, indicating that it interests the occurrence of disorder in organs as the consequence of an abnormally regulated immune system. IgG4-related disorder is a fibro-inflammatory state that can impact almost any organ system.
Market Dynamics: Drivers & Restraints
Increasing Market Developments
The increasing market developments are expected to boost the global market during the forecast period. For instance, in September 2023, Zenas BioPharma, a multinational biopharmaceutical corporation dedicated to evolving as a leader in the development and commercialization of immunology-based treatments, formed a license and partnership deal with Bristol Myers Squibb Company to design and commercialize obexelimab for autoimmune disorders in Japan, South Korea, Taiwan, Singapore, Hong Kong, and Australia.
Moreover, in November 2022, Zenas BioPharma secured a $118 million series B to skyrocket in on a pipeline of immune-based treatments and establish a phase 3 for its top nominee that was approved by Xencor the previous year. Additionally, the increase in product awareness, technological advancements, and increasing research activities with investments and funding are among the additional factors boosting the global market growth during the forecast period.
Stringent Regulatory Authorities
The stringent regulatory authorities authorizing the new drug treatments are expected to hamper the global market growth. Furthermore, high drug development costs and treatment side effects are also expected to hamper the global market growth in the forecast period.
Segment Analysis
The global IgG4-related disease market is segmented based on drug class, disease type, route of administration, distribution channel and region.
Biologics Drug Class is Expected to Dominate Market
Owing to the increase in the research activities for developing distinct biologics treatment options the biologics drug class segment is expected to dominate the global market during the forecast period. For instance, according to clinicaltrials.gov, presently a Phase 3 randomized, double-blind, multicenter, placebo-controlled assessment of Inebilizumab efficacy and safety in IgG4-related disease clinical trial is active and sponsored by the Viela Bio (acquired by Horizon Therapeutics) which is estimated to be completed by 2028.
Further, in January 2023, Zenas BioPharma, a multinational biopharmaceutical corporation dedicated to evolving as a top player in the expansion and commercialization of immune-based treatments dosed the first patient in the INDIGO Phase 3 registrational investigation of obexelimab.
Geographical Analysis
North America is Expected to Dominate the Global Market
Owing to the presence of key market players holding the majority of market share through performing distinct market tactics ensures the dominance of North America over the global market during the forecast period. For instance, in December 2022, Amgen a United States-based biopharmaceutical corporation acquired Horizon Therapeutics for about $27.8 billion, intended to replenish Amgen’s rare autoimmune, and inflammatory disorder portfolios as its top-selling drug starts to lose patent exclusivity in the forthcoming year. Further, according to the clinicaltrials.gov presently there are two phase 2 and one phase 3 clinical trials are recruiting while one phase 2 and one phase 3 clinical trial is active in the United States.
Market Segmentation
By Drug Class
• Corticosteroids
• Biologics
• Immunosuppressants
• Antimetabolites
• Others
By Disease Type
• Type 1 (IgG4-Related) Autoimmune Pancreatitis (AIP)
• Retroperitoneal IgG4-Related Tubulointerstitial Nephritis (TIN)
• IgG4-Related Tubulointerstitial Nephritis (TIN)
• Other IgG4-Related Disorders
By Route of Administration
• Injectable
• Oral
• Other
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In August 2023, Zenas BioPharma, published results from a Phase 2 investigation assessing obexelimab for the treatment of individuals with IgG4-Related Disease (IgG4-RD). Established on the outcomes of this investigation, a Phase 3 investigation in individuals with IgG4-RD is proceeding to additionally examine the effectiveness and safety of obexelimab administered as a subcutaneous injection.
• In March 2023, Pharmac, the Pharmaceutical Management Agency a New Zealand Crown entity began a planned on broadening sponsored access to rituximab (branded as Riximyo) for individuals with IgG4-related disease, a chronic inflammatory disorder.
Competitive Landscape
The major global players in the market include Pfizer Inc., AstraZeneca, Novartis AG, Zenas Biopharma, Amgen Inc., Bristol-Myers Squibb, Merck & Co., Inc., Sanofi S.A., Celltrion Healthcare Co., Ltd. and Cipla Inc. among others.
Why Purchase the Report?
• To visualize the global IgG4-related disease market segmentation based on drug class, disease type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of IgG4-related disease market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global IgG4-related disease market report would provide approximately 64 tables, 61 figures and 186 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Class
3.2. Snippet by Disease Type
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Market Developments
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Stringent Regulatory Authorities
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. Pipeline Analysis
5.8. Epidemiology
5.9. SWOT Analysis
5.10. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class
7.2. Corticosteroids*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Biologics
7.4. Immunosuppressants
7.5. Antimetabolites
7.6. Others
8. By Disease Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.1.2. Market Attractiveness Index, By Disease Type
8.2. Type 1 (IgG4-Related) Autoimmune Pancreatitis (AIP)*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retroperitoneal IgG4-Related Tubulointerstitial Nephritis (TIN)
8.4. IgG4-Related Tubulointerstitial Nephritis (TIN)
8.5. Other IgG4-Related Disorders
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Injectable*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Oral
9.4. Other
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Pfizer Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. AstraZeneca
13.3. Novartis AG
13.4. Zenas BioPharma
13.5. Amgen Inc.
13.6. Bristol-Myers Squibb
13.7. Merck & Co., Inc.
13.8. Sanofi S.A.
13.9. Celltrion Healthcare Co., Ltd.
13.10. Cipla Inc.
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us